←
Marc S. Raab201 posts
Marc S. Raab avatar

Marc S. Raab

@RaabMarc

Clinician and scientist focusing on multiple myeloma. Chair, GMMG study group. Tweets are my own. @HDMyeloma @ukhd @dkfz

◷ Joined April 2023▧ 23 Photos and videos
Henry C Fung| MM, lymphoma, leukemia & CART avatar
⟳ Marc S. Raab retweeted
Henry C Fung| MM, lymphoma, leukemia & CART@HenrychihangFu1·Nov 16

MajesTec5 RdMap👇 Could bispecifics—and now trispecifics—reshape frontline myeloma treatment? ✨ Back in May, I shared the #MagicTec roadmap. Now let’s zoom in on MajesTEC-5. One trial. Multiple cohorts. Several frontline questions: 🔹 What should induction look like? 🔹 How should we use these agents around ASCT? 🔹 What should maintenance contain? 🔹 Can selected strategies succeed without upfront ASCT? Clinical data are available from: • A/A1/B: teclistamab + Dara/Len ± bortezomib, followed by ASCT • E: talquetamab + Dara/Len, followed by ASCT • G: ramantamig + Dara/Len, followed by Ram–Dara without planned ASCT These are TRANSPLANT-ELIGIBLE patients—including arm G. MajesTEC-5 is exploring a redesign of the frontline treatment strategy. The transplant question is one part of that larger effort. Early responses are striking. Durability, toxicity, treatment burden and randomized comparisons will determine what changes practice. #MultipleMyeloma #ASH26 #Bispecifics #Trispecifics #HemeTwitter

Post attachment

It’s MajesTEC-1,2,3,4,5,7,9… but I call it #MagicTec ✨🧬 An easier way to remember the journey: 🔹 Magic 1 Advanced / heavily pretreated disease 🔹 Magic 3 1st+ relapse, non-Dara refractory (teclistamab + Dara moving earlier) 🔹 Magic 4 Maintenance after transplant 🔹 Magic 5 & 7 Frontline myeloma • transplant-eligible • transplant-ineligible 🔹 Magic 9 Dara-exposed / refractory early relapse strategy What is amazing is not just the speed… but the roadmap itself. The studies are progressively moving BCMA bispecific therapy: late line → early relapse → maintenance → frontline One scientific question at a time. One indication at a time. But accumulating very, very fast. ⚡ #MultipleMyeloma ##Bispecifics #HemeTwitter

Post attachment
Myeloma Society avatar
⟳ Marc S. Raab retweeted
Myeloma Society@Myeloma_Society·Sep 26

Marc Raab, MD, discussed cure in the context of the GEM14MAIN & MajesTEC-5 data shared during #IMS26. He also summarized studies on improving CAR-T safety and monitoring/managing bone disease during the Highlights session. @RaabMarc

Post attachment
Rahul Banerjee, MD, FACP avatar
⟳ Marc S. Raab retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Sep 25

#IMS26 Tal-DR in newly diagnosed ASCT-eligible myeloma. More excellent MajesTEC-5 by @RascheLeo @RaabMarc et al! 👏 No issues with SC collection. Excellent response 👇🏼. 15% ataxia (all low-grade & recovering) - perhaps combo Tx, or truly more common as tal enters earlier lines?

Post attachment
Heidelberg Myeloma avatar
⟳ Marc S. Raab retweeted
Heidelberg Myeloma@HDMyeloma·Sep 12

This weekend, we bid farewell to Hartmut Goldschmidt, who will retire from his academic positions at the end of the month. To celebrate 35 years of @HDMyeloma, 30 years of #GMMG, a large crowd joined us for a dedicated symposium with long-standing partners and friends. #mmsm

Post attachmentPost attachment
Saurabh Zanwar avatar
⟳ Marc S. Raab retweeted
Saurabh Zanwar@ZanwarSaurabh·Jun 28

GMMG-HD10/MajesTEC-5 represents an important and likely a watershed moment in myeloma induction and consolidation therapy! Amazing early and deep responses (100% MRD neg rates!!) 👏👏 @RascheLeo @RaabMarc et al. AntiCD38-based quadruplets set the bar pretty high for early PFS rates PFS and now we have a worthy challenger! Whether this eventually displaces autologous transplant or not, one thing is for sure—BCMA bispecifics in induction will certainly make all of us think like transplanters when it comes to our infectious disease game (>35% Gr3 infections, 6% CMV reactivation). Biggest question that will need answering is whether everyone need a BCMA TCE upfront and for how long? nature.com/articles/s41591-0…

Rahul Banerjee, MD, FACP avatar
⟳ Marc S. Raab retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Jun 26

Love seeing triple-digit MRD neg percentages 🤩 Congrats @RaabMarc et al on excellent MajesTEC-5 @NatureMedicine paper! bsAb-based induction in ND myeloma - may well obviate ASCT. Top panel = ITT, bottom = MRD-evaluable. Kudos to authors for reporting both sets like this.

Post attachment

#Myeloma Paper of the Day: Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples & post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) & 10-6 (46/46)); ORR was 100%: pubmed.ncbi.nlm.nih.gov/4235…. #mmsm

Post attachmentPost attachmentPost attachmentPost attachment
nizar jacques bahlis avatar
⟳ Marc S. Raab retweeted
nizar jacques bahlis@NBahlis·Jun 26

Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo nature.com/articles/s41591-0…

Mostafa Faisal avatar
⟳ Marc S. Raab retweeted
Mostafa Faisal@MostafaFaisal14·May 6

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy @BCD_AACR aacrjournals.org/bloodcancer…

Rahul Banerjee, MD, FACP avatar
⟳ Marc S. Raab retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Apr 9

Fascinating - albeit a little terrifying - @LeukemiaJnl work by 🇩🇪 How does GPRC5D loss affect surviving myeloma #MMsm clones? Here, remaining cells appear to be more aggressive. Will be important to validate / rebut as talquetamab moves into earlier lines... hopefully soon!

Post attachment